Selective A2A Adenosine Receptor Antagonists for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various disease states such as obesity, CNS disorders, cerebral ischemia, drug addiction, and immune response modulation are limited by the lack of selective A2A adenosine receptor antagonists that effectively target A2A receptors without causing side effects from interaction with other adenosine receptors.
Innovation Solution
Development of novel compounds, specifically those of Formula I, which are potent and selective A2A receptor antagonists, including structures like 6-[(1E)-2-(3,4-dimethoxyphenyl)vinyl]-3-ethyl-1,5-dimethyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione, for use in pharmaceutical formulations to treat conditions like Parkinson's disease, drug addiction, and cerebral ischemia, while preventing coronary steal and enhancing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If A2A receptor antagonists are used to treat disease states, then therapeutic efficacy is improved, but side effects occur due to interaction with other adenosine receptors
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (substituted bicyclic and tricyclic thieno[2,3-d]pyrimidine cores with particular R1-R6 substituents) that confer selective affinity for A2A receptors over other adenosine receptor subtypes (A1, A2B, A3). This molecular-level local differentiation enables the drug to act specifically on A2A receptors in the basal ganglia and other target tissues while minimizing off-target interactions, thereby maintaining therapeutic efficacy for Parkinson's disease and other indications while reducing side effects associated with non-selective adenosine receptor blockade.
2Reliability
If A2A receptor antagonists are developed, then treatment outcomes improve, but compound complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the A2A receptor antagonist molecule into distinct functional segments: a core thieno[2,3-d]pyrimidine bicyclic or tricyclic structure that provides baseline A2A affinity, and variable substituent groups (R1-R6) that can be independently optimized for selectivity, pharmacokinetics, and metabolic stability. This modular segmentation allows medicinal chemists to systematically modify individual segments to achieve desired treatment outcomes without redesigning the entire molecule, thereby managing compound complexity while improving therapeutic efficacy.
Solution Approach 2:
The patent applies parameter changes by systematically varying physical and chemical parameters of the A2A antagonist molecules, including substituent types (halogens, alkyl groups, aryl groups), substituent positions (R1 through R6), and molecular weight, to optimize the balance between treatment outcomes and compound complexity. By adjusting these parameters, the patent achieves high A2A selectivity and improved pharmacological properties while maintaining synthetically accessible structures that do not require overly complex synthesis routes.
Data Source
AI summary
The present invention relates to novel compounds that are A2A adenosine receptor antagonists having the structure of Formula Iand to their use in treating mammals for various disease states, such as obesity, CNS disorders, including the “movement disorders” (Parkinson's disease, Huntington's Chorea, and catelepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and drug addiction (alcohol, amphetamine, cannabinoids, cocaine, nicotine, and opioids) and to their use in the enhancement of immune response. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.